Author:
Liu Tong,Wang Xiang,Hu Wenquan,Fang Zhi,Jin Ying,Fang Xuedong,Miao Qing Robert
Reference64 articles.
1. Colorectal cancer: genetic abnormalities, tumor progression, tumor heterogeneity, clonal evolution and tumor-initiating cells;Testa;Med Sci (Basel),2018
2. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial;Heinemann;Lancet Oncol,2014
3. Overall survival of patients with advanced colorectal cancer correlates with availability of fluorouracil, irinotecan, and oxaliplatin regardless of whether doublet or single-agent therapy is used first line;Grothey;J Clin Oncol,2005
4. New lessons from "old" chemotherapy in colorectal cancer;Grothey;J Clin Oncol,2008
5. Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841;Franko;J Clin Oncol,2012
Cited by
33 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献